JPMorgan Chase & Co. Boosts Agilent Technologies (NYSE:A) Price Target to $165.00

Key Points

• JPMorgan Chase & Co. has raised its price target for Agilent Technologies from $155.00 to $165.00, indicating a potential upside of 17.46% from the current price.
• Agilent Technologies reported quarterly earnings of $1.37 per share, meeting analysts' expectations, with revenue increasing by 10.1% year-over-year to $1.74 billion.
• Several analysts have given Agilent a positive outlook, with UBS upgrading its rating to "buy" and setting a target price of $170.00, while the average price target among analysts is $148.69.

Agilent Technologies (NYSE:A - Get Free Report) had its price target raised by analysts at JPMorgan Chase & Co. from $155.00 to $165.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 17.46% from the company's current price.

A has been the subject of a number of other reports. UBS Group raised Agilent Technologies from a "neutral" rating to a "buy" rating and raised their target price for the stock from $130.00 to $170.00 in a research note on Wednesday. Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Agilent Technologies in a research note on Wednesday. Rothschild & Co Redburn initiated coverage on shares of Agilent Technologies in a report on Wednesday. They issued a "buy" rating and a $165.00 target price on the stock. Finally, Rothschild Redb raised shares of Agilent Technologies to a "strong-buy" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $148.69.

Agilent Technologies Trading Up 1.4%

A opened at $140.48 on Thursday. The firm has a market capitalization of $39.82 billion, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 4.52 and a beta of 1.26. The company's 50 day simple moving average is $124.07 and its two-hundred day simple moving average is $116.81. Agilent Technologies has a 1-year low of $96.43 and a 1-year high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the business earned $1.32 earnings per share. The business's revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts expect that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after buying an additional 4,362 shares during the period. Assenagon Asset Management S.A. increased its stake in Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. lifted its position in shares of Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares in the last quarter. D.A. Davidson & CO. boosted its stake in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. boosted its stake in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after purchasing an additional 54,302 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.